Interview with Paula Riedel, Partner, Linklaters LLP – EU Pharmaceutical Law 2014
We hear from Paula Riedel of Linklaters LLP on developments and challenges in EU Pharmaceutical Law, and what she believes would be the most interesting findings/outcomes of the Servier reverse payment patent settlement case. Paula will be speaking on ‘Reverse Payment Patent Settlements’ at EU Pharmaceutical Law Forum, 14th-15th May 2014. For more information, please …Read more »
Will (THC – Marijuanna) Help Treat Herpes?
GET YOUR FREE “HERPES SUCCESS FORMULA PROTOCOL” at: http://www.theundergroundcure.com See more videos on our channel: https://www.youtube.com/user/theonlyherpescure?v=HkoUqVmRlqw Email: undergroundcure@gmail.com PLEASE SUBSCRIBE, COMMENT, AND SHARE! THANKS “Disease is anaerobic. It cannot exist in an elevated oxygen environment” Is Herpes “incurable”? Who is telling us that? What is their motivation in telling us that Herpes is “incurable”? To …Read more »
The Big Pharma Deal- Continue To Look For Deals: Sun Pharma
Sun Pharmaceutical, India’s largest drugmaker by market value, has agreed to buy Ranbaxy in a $4 billion all-stock deal. Ranbaxy investors will get 0.8 share in Sun Pharma for every one of their shares. Agam Vakil shares details on the deal valuation and the shareholding pattern. Also, Bloomberg’s Ketaki Gokhale tells you what may happen …Read more »
FDA Basics: John Jenkins, MD on the Development, Testing, and Monitoring of New Drugs?
John Jenkins is Director of the Office of New Drugs at the Center for Drug Evaluation and Research. “Its very important for people to understand,” says Jenkins, “that we dont know everything about new drugs at the time we approve them. [I]f we waited until we knew everything you could possibly know, then the wait …Read more »
Motif Bio confident about partner interest in Iclaprim
Graham Lumsden, chief executive of Motif Bio (LON:MTFB), tells Proactive Investors he is confident about the path forward for Iclaprim. After a ‘collaborative meeting’ with the FDA, the American regulator gave the biopharmaceutical company the green light to begin phase 111 clinical trials on its next-generation antibiotic. Lumsden is now putting together a strategic business …Read more »